J
Judith Barash
Researcher at Kaplan Medical Center
Publications - 19
Citations - 1017
Judith Barash is an academic researcher from Kaplan Medical Center. The author has contributed to research in topics: Rheumatic fever & Rheumatology. The author has an hindex of 13, co-authored 19 publications receiving 853 citations. Previous affiliations of Judith Barash include Meir Medical Center.
Papers
More filters
Journal ArticleDOI
Mutant Adenosine Deaminase 2 in a Polyarteritis Nodosa Vasculopathy
Paulina Navon Elkan,Sarah B. Pierce,Reeval Segel,Reeval Segel,Tom Walsh,Judith Barash,Shai Padeh,Abraham Zlotogorski,Yackov Berkun,Joseph J. Press,Mukamel M,Isabel Voth,Philip J. Hashkes,Liora Harel,Vered Hoffer,Eduard Ling,Fatoş Yalçınkaya,Ozgur Kasapcopur,Ming K. Lee,Rachel E. Klevit,Paul Renbaum,Ariella Weinberg-Shukron,Ariella Weinberg-Shukron,Elif Funda Sener,Elif Funda Sener,Barbara Schormair,Sharon Zeligson,Dina Marek-Yagel,Tim M. Strom,Mordechai Shohat,Mordechai Shohat,Amihood Singer,Alan Rubinow,Elon Pras,Juliane Winkelmann,Juliane Winkelmann,Mustafa Tekin,Yair Anikster,Mary Claire King,Ephrat Levy-Lahad,Ephrat Levy-Lahad +40 more
TL;DR: Recessive loss-of-function mutations of ADA2, a growth factor that is the major extracellular adenosine deaminase, can cause polyarteritis nodosa vasculopathy with highly varied clinical expression.
Journal ArticleDOI
Antiphospholipid syndrome and recurrent thrombosis in children.
Yackov Berkun,Shai Padeh,Judith Barash,Yosef Uziel,Liora Harel,Mukamel M,Shoshana Revel-Vilk,Gili Kenet +7 more
TL;DR: APS in children has unique features, and SLE may develop in a significant percentage of girls presenting with APS, whereas the preventive impact of anticoagulant treatment following the first thrombotic event was noteworthy.
Journal ArticleDOI
Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials
Nicolino Ruperto,Hermine I. Brunner,Pierre Quartier,Tamás Constantin,Nico M Wulffraat,Gerd Horneff,Ozgur Kasapcopur,Rayfel Schneider,Jordi Anton,Judith Barash,Reinhard Berner,Fabrizia Corona,Ruben Cuttica,Marine Fouillet-Desjonqueres,Michel Fischbach,Helen E. Foster,Dirk Foell,Sebastião Cezar Radominski,Athimalaipet V Ramanan,Ralf Trauzeddel,Erbil Unsal,Jeremy Levy,Eleni Vritzali,Alberto Martini,Daniel J. Lovell +24 more
TL;DR: Response to canakinumab treatment was sustained and associated with substantial glucocorticoid dose reduction or discontinuation and a relatively low retention-on-treatment rate, and no new safety findings were observed.
Journal ArticleDOI
Naproxen as an alternative to aspirin for the treatment of arthritis of rheumatic fever: a randomized trial.
Philip J. Hashkes,Tsivia Tauber,Eli Somekh,Riva Brik,Judith Barash,Masza Mukamel,Liora Harel,Abraham Lorber,Matityahu Berkovitch,Yosef Uziel +9 more
TL;DR: It is concluded that naproxen is as effective, is easier to use, and is safer than aspirin in the treatment of the arthritis of rheumatic fever.
Journal ArticleDOI
A longitudinal PRINTO study on growth and puberty in juvenile systemic lupus erythematosus
Marite Rygg,Angela Pistorio,Angelo Ravelli,Mohamad Maghnie,Natascia Di Iorgi,Brigitte Bader-Meunier,Carlos Da Silva,Rosa Roldan-Molina,Judith Barash,Cristina Dracou,Sylvie Gandon Laloum,Katerina Jarosova,Chantal Job Deslandre,Isabelle Koné-Paut,Franco Garofalo,Joseph Press,Claudia Sengler,Tsivia Tauber,Alberto Martini,Nicolino Ruperto +19 more
TL;DR: The children at risk of having a negative effect on height and pubertal development are prepubertal and peripubertals children treated with >400 mg/kg cumulative dose of corticosteroids.